Skip to main content

Table 1 Features of the study population

From: Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial

subject

No.

gender

age

[years]

height

[cm]

weight

[kg]

BMI

FEV1

[%]

therapy

Asthma

severity

1

female

27

161

52

20.1

98.0

BoD

<1/w

2

female

27

170

64

22.1

104.0

BoD

<1/w

3

female

29

170

70

24.2

94.0

-

<1/w

4

female

28

166

54

19.6

109.0

-

<1/w

5

male

22

187

85

24.3

127.0

-

<1/w

6

male

34

176

80

25.8

118.0

-

<1/w

7

female

27

166

59

21.4

82.7

BoD

<1/w

8

female

31

180

66

20.4

97.0

-

<1/w

9

female

49

163

65

24.4

99.0

BoD

<1/w

  1. BoD = betamimetic inhalation on demand; <1/w = less than one exacerbation/week & no limitation of activities
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us